IDEXX Laboratories, Inc. vs Yum China Holdings Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Yum China Holdings Inc trades at $42.88 (market cap $14.11B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.9× Yum China Holdings Inc's market cap, and Yum China Holdings Inc pays a 2.78% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Yum China Holdings Inc for 77 Days on average.
| IDXX | YUMC | |
|---|---|---|
Market Cap | $40.43B | $14.11B |
Volume | 692,164 | 2,350,650 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $57.95 |
52-Week Low | $504.70 | $39.98 |
Typical Hold Time | 46 Days | 77 Days |
Enterprise Value | $41.32B | $15.02B |
Dividend Yield | — | 2.78% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
YUMC trades at $42.92, up 5.58% today, with strong analyst support (73.68% buy ratings) but technical indicators show bearish momentum. The company demonstrates solid fundamentals with consistent revenue growth from $9.6B in 2022 to $11.8B in 2025, and net income improving to $929M. Recent strategic moves include the $1.2B acquisition of Pizza Hut China brand ownership and expansion of Pizza Hut Burger Bars to 300 locations.
YUMC presents a value opportunity with reasonable valuation (P/E 15.3, P/S 1.2) and strong profitability (ROE 17.5%), though technical weakness and China economic exposure pose near-term risks. The stock's 25.6% analyst upside potential and consistent earnings beats support long-term growth prospects despite current bearish technical signals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →